- Previous Close
269.62 - Open
267.71 - Bid --
- Ask --
- Day's Range
264.45 - 269.60 - 52 Week Range
148.00 - 310.00 - Volume
303,545 - Avg. Volume
486,274 - Market Cap (intraday)
10.305B - Beta (5Y Monthly) 0.51
- PE Ratio (TTM)
764.46 - EPS (TTM)
0.35 - Earnings Date May 5, 2025 - May 9, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
310.35
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, and aspiration pump under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as detachable coils to treat patients with a wide range of neurovascular lesions under the Penumbra SMART COIL and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
www.penumbrainc.comRecent News: PEN
View MorePerformance Overview: PEN
Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PEN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PEN
View MoreValuation Measures
Market Cap
10.31B
Enterprise Value
10.19B
Trailing P/E
743.22
Forward P/E
73.53
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.79
Price/Book (mrq)
8.95
Enterprise Value/Revenue
8.53
Enterprise Value/EBITDA
221.54
Financial Highlights
Profitability and Income Statement
Profit Margin
1.17%
Return on Assets (ttm)
4.84%
Return on Equity (ttm)
1.20%
Revenue (ttm)
1.19B
Net Income Avi to Common (ttm)
14.01M
Diluted EPS (ttm)
0.35
Balance Sheet and Cash Flow
Total Cash (mrq)
340.13M
Total Debt/Equity (mrq)
19.41%
Levered Free Cash Flow (ttm)
143.8M